
Editas Medicine is a clinical‑stage biotechnology company that harnesses CRISPR/Cas9 and Cas12a genome‑editing platforms to develop durable, precision therapies for genetic and blood disorders, including sickle cell disease, beta‑thalassemia, and ocular conditions. The company’s pipeline spans in‑vivo editing, engineered cell medicines, and hematopoietic stem‑cell therapies, aiming to translate cutting‑edge genomics into first‑in‑class treatments. Editas differentiates itself through a cohesive, collaborative culture—referred to as "One Editas"—and a dedicated team of scientists who prioritize patient impact and scientific rigor. With a robust manufacturing and commercialization strategy, the firm is positioned to bring transformative genomic medicines to patients worldwide.
We are pioneering the possible and translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of medicines for people living with serious diseases. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
Editas Medicine is a clinical‑stage biotechnology company that harnesses CRISPR/Cas9 and Cas12a genome‑editing platforms to develop durable, precision therapies for genetic and blood disorders, including sickle cell disease, beta‑thalassemia, and ocular conditions. The company’s pipeline spans in‑vivo editing, engineered cell medicines, and hematopoietic stem‑cell therapies, aiming to translate cutting‑edge genomics into first‑in‑class treatments. Editas differentiates itself through a cohesive, collaborative culture—referred to as "One Editas"—and a dedicated team of scientists who prioritize patient impact and scientific rigor. With a robust manufacturing and commercialization strategy, the firm is positioned to bring transformative genomic medicines to patients worldwide.